Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 29, 2013

View Archived Issues

Ugimers as novel antisense drugs with improved solubility and cell wall penetration properties

Discovery of novel NMDA modulators for the treatment of neurological disorders

CSL Behring launches DNA1 Advanced Alpha-1 Screening test

Editas Medicine secures financing for genome editing technology

Characterization of a third-generation tyrosine kinase inhibitor to overcome cancer drug resistance

European FP7 research grant for BIOIMAGE-NMD project in rare neuromuscular diseases

SillaJen to acquire Jennerex

Immatics presents preliminary phase I results for the novel cancer vaccine IMA-950

CardioPharma cardiovascular disease capsule shows bioequivalence

ARMO BioSciences begins phase I study of AM-0100 in advanced solid tumors

Chinese researchers present novel apoptosis inhibitors

FDA grants orphan drug exclusivity for Treanda for indolent B-cell NHL

New lpxC inhibitors for bacterial infections synthesized at Achaogen

Lycera Corp. and Merck & Co. divulge novel RORgamma antagonists

Merck & Co. prepares new CGRP antagonists for migraine

Bayer files for Japanese approval of VEGF Trap-Eye for myopic CNV

EN-3356, a novel CYP17A inhibitor for the treatment of castration-resistant prostate cancer

FDA awards fast track designation to VB-111 for recurrent GBM

Development of a new compound to assess the nociceptive function of a chloride channel

Orexigen plans resubmission of Contrave NDA based on interim analysis of Light Study

Isis Pharmaceuticals begins phase I study of ISIS-GSK3Rx

Merrimack Pharmaceuticals reports data from two phase II breast cancer studies

Janssen Pharma launches new formulation of darunavir in Japan

Lilly launches Strattera oral solution in Japan

EMA accepts Fibrocaps MAA for review

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...